In the CD73 axis, the phase 2 COAST platform trial suggested that adding the anti-CD73 antibody oleclumab to durvalumab as consolidation after chemoradiation increased ORR and prolonged PFS versus durvalumab alone in unresectable stage III NSCLC [33], a signal now being tested in phase 3 (PACIFIC-9). Here, NT5E is linked to non-small cell lung carcinoma.